Drug class
Meningococcal Vaccines - Serogroup B
Meningococcal Vaccines - Serogroup B comprise an immunologic class of recombinant protein-based vaccines designed for active immunization against *Neisseria meningitidis* serogroup B. Read more about Meningococcal Vaccines - Serogroup B
8 drugs in this class 3 manufacturers
Drugs in Meningococcal Vaccines - Serogroup B
TRUMENBA (Neisseria meningitidis group B, lipidated fHBP recombinant)
PENBRAYA (PF) (meningococ A,C,Y,W-135,TT comp/N. mening B,fHBP rec comp/PF)
PENBRAYA MENB COMPONENT (PF) (Neisseria meningitidis B (A05 & B01), (fHBP), rec component)
PENBRAYA (meningococ A,C,Y,W-135,TT comp/N. mening B,fHBP rec comp/PF)
PENBRAYA MENB COMPONENT (Neisseria meningitidis B (A05 & B01), (fHBP), rec component)
PENMENVY MEN A-B-C-W-Y (meningoc A,C,Y,W-135,DT cmp/N.mening B NHBA,NadA,fHBP,OMV/PF)
PENMENVY MENB COMPONENT (Neisseria meningitidis group B (NHBA, NadA, fHBP, OMV) comp)
Meningococcal Vaccines - Serogroup B comprise an immunologic class of recombinant protein-based vaccines designed for active immunization against *Neisseria meningitidis* serogroup B.
Because the serogroup B capsular polysaccharide mimics human neural tissue and is poorly immunogenic, these vaccines instead present surface-exposed bacterial proteins—such as factor H binding protein, neisserial adhesin A, neisseria heparin-binding antigen, and outer membrane vesicles—to stimulate serum bactericidal antibodies that mediate complement-dependent bacterial lysis.
Clinically, this class is utilized to prevent life-threatening invasive meningococcal disease, primarily acute bacterial meningitis and meningococcemia, in adolescents, young adults, and individuals at heightened risk due to anatomical or functional asplenia, persistent complement component deficiencies, or outbreak exposure.
-
fda.gov
Meningococcal Vaccines - Serogroup B comprise an immunologic class of recombinant protein-based vaccines designed for active immunization against *Neisseria meningitidis* serogroup B
-
fda.gov
Meningococcal Vaccines - Serogroup B comprise an immunologic class of recombinant protein-based vaccines designed for active immunization against *Neisseria meningitidis* serogroup B
-
justtheinserts.com
Meningococcal Vaccines - Serogroup B comprise an immunologic class of recombinant protein-based vaccines designed for active immunization against *Neisseria meningitidis* serogroup B. Because the serogroup B capsular polysaccharide mimics human neural tissue and is poorly immunogenic, these vaccines instead present surface-exposed bacterial proteins—such as factor H binding protein, neisserial adhesin A, neisseria heparin-binding antigen, and outer membrane vesicles—to stimulate serum bactericid...
-
who.int
Meningococcal Vaccines - Serogroup B comprise an immunologic class of recombinant protein-based vaccines designed for active immunization against *Neisseria meningitidis* serogroup B. Because the serogroup B capsular polysaccharide mimics human neural tissue and is poorly immunogenic, these vaccines instead present surface-exposed bacterial proteins—such as factor H binding protein, neisserial adhesin A, neisseria heparin-binding antigen, and outer membrane vesicles—to stimulate serum bactericid...
-
meningvax.com
Meningococcal Vaccines - Serogroup B comprise an immunologic class of recombinant protein-based vaccines designed for active immunization against *Neisseria meningitidis* serogroup B. Because the serogroup B capsular polysaccharide mimics human neural tissue and is poorly immunogenic, these vaccines instead present surface-exposed bacterial proteins—such as factor H binding protein, neisserial adhesin A, neisseria heparin-binding antigen, and outer membrane vesicles—to stimulate serum bactericid...
-
fda.gov
Clinically, this class is utilized to prevent life-threatening invasive meningococcal disease, primarily acute bacterial meningitis and meningococcemia, in adolescents, young adults, and individuals at heightened risk due to anatomical or functional asplenia, persistent complement component deficiencies, or outbreak exposure
-
cdc.gov
Clinically, this class is utilized to prevent life-threatening invasive meningococcal disease, primarily acute bacterial meningitis and meningococcemia, in adolescents, young adults, and individuals at heightened risk due to anatomical or functional asplenia, persistent complement component deficiencies, or outbreak exposure
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.